Pay in 4 interest-free payments of $6.12 Learn more
Ships within 48 hours · Estimated delivery Oct 11 - Oct 16
Is the risk clinically significant
Other GLP-1 and glucagon co-agonists in early phase clinical trials as treatments for obesity include AZD9550 and LY3305677 (NCT05623839)
Coverage scope: How widely this plan will be applied for Medicare beneficiaries is still being clarified
10.3233/JPD-181503 J
Glucagon receptor activation is minimal at 1-2mg but increases significantly at 4mg and becomes a major driver of the metabolic profile at 8mg and above
US$ 27.67
US$ 25.10
US$ 28.86
US$ 28.59
US$ 20.30
US$ 23.04
US$ 22.80
